Abstract:Background: Delays in breast cancer diagnosis and treatment lead to worse survival and quality of life decrements. Racial disparities in care timeliness have been reported, but few studies have examined access at multiple points along the care continuum (diagnosis, treatment initiation, treatment duration, and genomic testing). Methods: The Carolina Breast Cancer Study Phase 3 (CBCS3) is a population-based cohort (n=2998, 50% Black) with invasive breast cancer diagnoses (2008-2013). We used latent class analysis (LCA) to group participants based on patterns of factors within 3 separate domains: "socio-economic status (SES)", "care barriers", and "care use." These classes were evaluated in association with delayed diagnosis (approximated with stage 3 or 4 at diagnosis), delayed treatment initiation (more than 30 days between diagnosis and first treatment), prolonged treatment duration (time between first and last treatment – by treatment modality), and receipt of OncotypeDx genomic testing (evaluated among patients with early stage, ER+, HER2- disease). Associations were evaluated using adjusted linear-risk regression to estimate relative frequency differences (RFDs) with 95% confidence intervals (CIs). Results: Overall, 18% of CBCS participants had late stage/delayed diagnosis, 35% had delayed treatment initiation, 48% had prolonged treatment duration, and 62% did not receive OncotypeDx. Black women had greater frequency of each unfavorable care outcome compared to non-Black women, including diagnostic delay (22% vs 15%, RFD= 6.9, 4.1-9.6), treatment initiation delay (39% vs 31%, RFD=7.9, 4.5-11.3), prolonged treatment (50% vs 46%, RFD= 4.3, 0.5-8.2), and OncotypeDx non-receipt (69% vs 57%, RFD= 12.2, 7.3-16.7). We identified 3 latent classes for SES ("high SES", "moderate SES," and "low SES") 2 classes for care barriers ("few barriers", "more barriers"), and 5 classes for care use ("short travel/high preventive care", "short travel/low preventive care," "medium travel," "variable travel," and "high travel"). Low-SES and more barriers to care were associated with greater frequency of delayed diagnosis (RFDadj = 5.5, 2.4-8.5; RFDadj =6.7, 2.8-10.7, respectively) and prolonged treatment (RFDadj = 9.7, 4.8-14.6; RFDadj = 7.3, 2.4-12.2, respectively). Variable travel (short time to diagnosis but long time to surgery) was associated with delayed treatment in the entire study population (RFDadj = 10.7, 2.7-18.8) compared to the short travel, high use referent group. The high travel group (representing long travel to both diagnosis and surgery) was associated with delayed treatment only among Black women relative to the same referent group (RFDadj = 10.0, -3.3-23.2). Conclusions: Black patients face more frequent delays throughout the care continuum, likely stemming from different types of access barriers at key junctures. Improving breast cancer care access will require intervention on multiple aspects of SES and healthcare access. Citation Format: Matthew R. Dunn, Didong Li, Marc A Emerson, Caroline A. Thompson, Hazel B Nichols, Sarah C Van Alsten, Mya L. Roberson, Lisa A. Carey, Terry Hyslop, Jennifer Elston Lafata, Melissa A. Troester. The heterogenous impact of healthcare access factors throughout the breast cancer care continuum [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl) nr C135.

An assessment of the association between patient characteristics and timely lung cancer treatment

Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries with Metastatic Non-Small-Cell Lung Cancer

Access to Care Metrics in Stage I Lung Cancer: Improved Access Is Associated With Improved Survival

Utilization Pattern and Service Settings of Palliative Care for Patients with Metastatic Non–small Cell Lung Cancer

Geographic variation in palliative care delivery among patients diagnosed with metastatic lung cancer in the USA: Medicare population-based study

Abstract 2237: Determinants of time to cancer treatment initiation at a comprehensive cancer center

Characteristics associated with early vs. late adoption of lung cancer screening

An assessment of the association between patient race and prior authorization program determinations in the context of radiation therapy

Factors associated with delays in care of suspicious lung nodules at an academic medical center.

Surgeon Care Team Network Measures and Timely Breast Cancer Treatment

Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real‐world databases

Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care

Abstract 4793: Effects of treatment delays on lung cancer survival

Abstract 799: Area-level socioeconomic deprivation is associated with inadequate access to quality preoperative care and increased readmission after surgery for early-stage lung cancer

Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers

Abstract C126: Disparities in time-to-treat insured patients with newly diagnosed cancer in a vertically integrated healthcare system

Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery

Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis

Abstract C135: The heterogenous impact of healthcare access factors throughout the breast cancer care continuum

Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?

Quality of Treatment Selection for Medicare Beneficiaries With Cancer